Agios Pharmaceuticals (AGIO)
NASDAQ:AGIO
Want to see AGIO full AI Analyst Report?
AGIO Stock Chart & Stats
$35.14
-$0.03(-0.09%)
At close: 4:00 PM EST
$35.14
-$0.03(-0.09%)
Day’s Range― - ―
52-Week Range$22.24 - $46.00
Previous CloseN/A
Volume212.48K
Average Volume (3M)941.53K
Market Cap
$2.25B
Enterprise Value$1.89B
Total Cash (Recent Filing)$737.04M
Total Debt (Recent Filing)$35.74M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Jul 30, 2026EPS Estimate
-1.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.25
Shares Outstanding59,471,607
10 Day Avg. Volume1,233,181
30 Day Avg. Volume941,530
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.32
Price to Sales (P/S)29.21
P/FCF Ratio-4.18
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue28.61
Enterprise Value/Gross Profit34.86
Enterprise Value/Ebitda-4.52
Forecast
1Y Price Target
$38.14Price Target Upside8.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-6.23
Revenue Forecast (FY)$121.95M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Strong Gross MarginSustained top‑line growth (Q1 +138% YoY; TTM +22%) combined with an ~88% gross margin indicates the business converts sales to high incremental gross profit. That margin durability supports scalable commercial investment and long‑term margin recovery as volumes rise, aiding sustainable cash generation.
Robust Balance Sheet And Low LeverageA >$1B liquidity reserve and very low leverage provide meaningful runway to fund R&D, confirmatory trials and commercialization without immediate refinancing. This financial flexibility reduces short‑term solvency risk and allows management to execute clinical and commercial milestones over the next 2–6 months.
Proven Launch & Commercial ExecutionRapid REMS onboarding and early prescriber adoption demonstrate practical commercial capabilities in complex specialty channels. Successful REMS execution and patient support imply sustainable go‑to‑market processes that materially increase the odds of durable uptake as the launch expands beyond early adopters.
Bears Say
Persistent High Cash BurnOperating cash flows and free cash flows are deeply negative and have persisted across multiple years. Even with current liquidity, sustained -$300M+ annual cash burn forces either rapid revenue scaling or external financing, increasing dilution or refinancing risk over the medium term if product uptake slows.
Deep And Volatile Losses; Weak ProfitabilityExtremely negative operating margins and a large TTM net loss show expenses far exceed current revenue. The volatility (an isolated profitable year amid large losses) reduces earnings quality and limits the firm's ability to generate returns on invested capital absent consistent commercial scale.
Development And Regulatory UncertaintyA significant PK exposure gap for tebapivat necessitates dose exploration, and accelerated pathways for mitapivat hinge on confirmatory trials. These development and regulatory contingencies can delay approvals, raise costs, and allow competitors to encroach, affecting long‑term commercial prospects.
Agios Pharma News
AGIO FAQ
What was Agios Pharmaceuticals’s price range in the past 12 months?
Agios Pharmaceuticals lowest stock price was $22.24 and its highest was $46.00 in the past 12 months.
What is Agios Pharmaceuticals’s market cap?
Agios Pharmaceuticals’s market cap is $2.25B.
When is Agios Pharmaceuticals’s upcoming earnings report date?
Agios Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 32 days.
How were Agios Pharmaceuticals’s earnings last quarter?
Agios Pharmaceuticals released its earnings results on Apr 29, 2026. The company reported -$1.69 earnings per share for the quarter, beating the consensus estimate of -$1.803 by $0.113.
Is Agios Pharmaceuticals overvalued?
According to Wall Street analysts Agios Pharmaceuticals’s price is currently Undervalued.
Does Agios Pharmaceuticals pay dividends?
Agios Pharmaceuticals does not currently pay dividends.
What is Agios Pharmaceuticals’s EPS estimate?
Agios Pharmaceuticals’s EPS estimate is -1.67.
How many shares outstanding does Agios Pharmaceuticals have?
Agios Pharmaceuticals has 59,471,607 shares outstanding.
What happened to Agios Pharmaceuticals’s price movement after its last earnings report?
Agios Pharmaceuticals reported an EPS of -$1.69 in its last earnings report, beating expectations of -$1.803. Following the earnings report the stock price went up 13.105%.
Which hedge fund is a major shareholder of Agios Pharmaceuticals?
Currently, no hedge funds are holding shares in AGIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agios Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.14 (8.55% Upside)
$38.14 (8.55% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 388.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.63%
12-Months-Change
Fundamentals
Return on Equity
-34.11%
Trailing 12-Months
Asset Growth
-23.82%
Trailing 12-Months
Company Description
Agios Pharmaceuticals
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
AGIO Company Deck
AGIO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong early commercial momentum and significant regulatory and pipeline progress—highlighted by 138% YoY revenue growth, a successful AQVESME U.S. launch with 242 prescriptions, planned sNDA submission for mitapivat in sickle cell disease, and a robust cash position (> $1B). Offsetting items included rising R&D and SG&A spend, limited ex‑U.S. revenue and quarter‑to‑quarter variability, a prescription‑to‑initiation lag as launch broadens, a 60% lower tebapivat exposure signal in low‑risk MDS necessitating higher‑dose evaluation, and some regulatory/competitive uncertainty that will need to be resolved by upcoming data and confirmatory trials. Overall, the positives (strong growth, launch execution, regulatory progress and ample liquidity) materially outweigh the near‑term challenges and risks.View all AGIO earnings summariesAGIO Stock 12 Month Forecast
Average Price Target
$38.14
▲(8.55% Upside)
Technical Analysis
ImmunityBio
―
Denali Therapeutics
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Apogee Therapeutics
―
Ownership Overview
1.15% Insiders
26.35% Mutual Funds
51.63% Other Institutional Investors
1.12% Public Companies and
Individual Investors